Benitec Biopharma Inc. financial data

Symbol
BNTC on Nasdaq
Industry
Pharmaceutical Preparations
Location
3940 Trust Way, Hayward, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q2 2024 - Sep 26, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 608 % +95.9%
Debt-to-equity 19.8 % -60.2%
Return On Equity -90.1 % +67.1%
Return On Assets -75.3 % +58.9%
Operating Margin -22.6K % +62.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.6M shares +310%
Common Stock, Shares, Outstanding 1.67M shares 0%
Entity Public Float 8.37M USD +76%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 4.06M shares +193%
Weighted Average Number of Shares Outstanding, Diluted 4.06M shares +193%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Research and Development Expense 15.6M USD +22.2%
General and Administrative Expense 6.99M USD +9.51%
Operating Income (Loss) -22.5M USD -17.9%
Nonoperating Income (Expense) 739K USD
Net Income (Loss) Attributable to Parent -21.8M USD -11.2%
Earnings Per Share, Basic -5.51 USD/shares +61%
Earnings Per Share, Diluted -5.51 USD/shares +61%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 50.9M USD +1954%
Other Assets, Current 516K USD -56.4%
Assets, Current 51.7M USD +1286%
Property, Plant and Equipment, Net 179K USD +106%
Operating Lease, Right-of-Use Asset 270K USD -48.7%
Other Assets, Noncurrent 62K USD -36.1%
Assets 52.2M USD +1070%
Employee-related Liabilities, Current 475K USD +0.64%
Liabilities, Current 4.92M USD +23.8%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 4.96M USD +16.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -892K USD -7.47%
Retained Earnings (Accumulated Deficit) -190M USD -13.3%
Stockholders' Equity Attributable to Parent 47.2M USD +23290%
Liabilities and Equity 52.2M USD +1070%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.58M USD -13.2%
Net Cash Provided by (Used in) Financing Activities 27.9M USD +74.3%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 160M shares 0%
Common Stock, Shares, Issued 10.1M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.4M USD +87.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 50.9M USD +1945%
Deferred Tax Assets, Valuation Allowance 20.6M USD -6.06%
Deferred Tax Assets, Gross 21M USD -6.02%
Operating Lease, Liability 284K USD -49.2%
Depreciation 19K USD -54.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -21.8M USD -13.9%
Lessee, Operating Lease, Liability, to be Paid 291K USD -50.3%
Property, Plant and Equipment, Gross 1.58M USD +12.7%
Operating Lease, Liability, Current 284K USD +3.27%
Lessee, Operating Lease, Liability, to be Paid, Year Two 291K USD -3.96%
Lessee, Operating Lease, Liability, to be Paid, Year One 291K USD -1.36%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7K USD -74.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 62K USD -18.4%
Deferred Tax Assets, Operating Loss Carryforwards 14.5M USD -21.3%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 68K USD +9.68%
Depreciation, Depletion and Amortization 87K USD -36%
Share-based Payment Arrangement, Expense 830K USD +83.6%